Kalaris Therapeutics Inc (KLRS) Stock Analysis
Verdict: WATCH (do not buy)
Strong insider buying and a $98M cash runway fight against a -46% 90-day price collapse; the model sees a high-risk bottom-fishing play.
Investment score: 44/100
Analysis as of
Is Kalaris Therapeutics Inc stock worth reviewing? AI model thesis
KLRS is a 'show-me' story with a solid balance sheet but poor market sentiment. The model views the recent insider buying as a critical floor-setting signal.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Kalaris Therapeutics Inc opportunities and risks
What speaks for KLRS
- Substantial Cash Runway
What speaks against KLRS
- Binary Clinical Outcome Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KLRS | n/a | 0.0x | n/a | 0.0% | 0.0% | -53.3% |
| CRDF | n/a | 231.8x | n/a | -2147.8% | -8527.2% | -30.8% |
| HSTC | n/a | 63.2x | n/a | 71.9% | -107.6% | -4.3% |
| COYA | n/a | 11.0x | 2317.6x | 99.8% | -266.1% | -16.1% |
| INO | n/a | 0.0x | n/a | 0.0% | 0.0% | -115.5% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.2% |
| Peer median | n/a | 11.0x | n/a | 0.0% | -107.6% | -16.1% |
Frequently asked questions about Kalaris Therapeutics Inc (KLRS)
Is KLRS stock a good investment?
The cached TradeMates AI model rates Kalaris Therapeutics Inc as WATCH (do not buy) with an investment score of 44/100. KLRS is a 'show-me' story with a solid balance sheet but poor market sentiment. The model views the recent insider buying as a critical floor-setting signal. This is algorithmic model output, not personal investment advice.
Is KLRS stock a buy?
The TradeMates model verdict for KLRS is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.